Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
Do you recommend prophylactic ureteral stenting in patients who have recently completed SBRT to a region in close proximity to the ureter prior to the potential development of fibrosis?
Answer from: Radiation Oncologist at Community Practice
No, just F/U MRI.
Sign in or Register to read more
12725
Related Questions
What is your preferred approach in a patient unable to fill their bladder during prostate radiotherapy?
Given the different rates of testosterone recovery, do you alter the duration of ADT when using Leuprorelin (GnRH Agonist) vs relugolix (GnRH antagonist) in patients with intermediate or high-risk prostate cancer who received definitive radiation?
How would you manage an aortocaval nodal recurrence of prostate cancer in a patient who previously received salvage radiation to the fossa and pelvic nodes?
Which genomic test do you choose for a patient with favorable intermediate prostate cancer trying to decide between active surveillance and treatment?
Are patients with MIBC and bladder neck involvement good candidates for bladder preservation with chemoradiation after maximal, but not complete, TURBT?
How would you manage sarcomatoid carcinoma of the prostate with poorly differentiated adenocarcinoma that is not amenable to surgery?
Given results of the RADICALS trials, is LT-ADT standard of care for salvage prostate RT?
In asymptomatic patients with castrate resistant prostate cancer who have failed chemotherapy and have progressive vertebral body metastases, when do you prescribe lutetium-177 vs prophylactic spinal radiation?
What is your experience with Pylarify vs. Posluma PSMA PET for prostate cancer and is one preferred over the other?
How do you approach Lu-177 use in taxane-naive patients with metastatic prostate cancer?